IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
Rhea-AI Summary
IgniteData has partnered with AstraZeneca (AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH) to implement its Archer platform in an ongoing Phase 3 study. The platform automates data transfer between hospital Electronic Health Records and sponsor Electronic Data Capture systems.
The collaboration, which began in 2021, follows successful pilot studies at University College London Hospitals and Memorial Sloan Kettering Cancer Center. Archer's system-agnostic design can map hundreds of data points per patient while maintaining data security and privacy.
The platform aims to reduce time spent on manual data entry, allowing researchers to focus more on clinical research. This implementation at Cambridge marks a significant step in scaling the technology across NHS and European hospitals for future clinical trials.
Positive
- Implementation of automated data transfer system could reduce operational costs and improve efficiency in AZN's clinical trials
- Successful pilot studies at major medical centers demonstrate platform's viability
- Potential for global scaling across hospitals could accelerate clinical trial processes
Negative
- Initial implementation to single Phase 3 study
- Return on investment and actual cost savings not yet quantified
News Market Reaction
On the day this news was published, AZN declined 0.30%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
IgniteData's Archer tool is a technology platform that upholds the highest standards of data security and automates the data transfer process between hospital Electronic Health Records (EHRs) and sponsor Electronic Data Capture (EDCs), allowing researchers to focus more of their time on clinical research and less time on data entry. With its system-agnostic design, Archer integrates effortlessly with leading EHRs and EDCs to map a multitude of study variables and transfer several hundred data points per patient, resulting in significant time savings while ensuring the highest levels of data integrity and maintaining patient data privacy.
The collaboration between Cambridge University Hospitals, AstraZeneca, and IgniteData began in 2021, with AstraZeneca playing a key role in developing the Archer platform. After successful pilot studies at University College London Hospitals (UCLH) and Memorial Sloan Kettering Cancer Center (MSK), Archer is now being deployed in this pivotal study at
Richard Yeatman, COO of IgniteData, added, "Our partnership with Cambridge University Hospitals and AstraZeneca is a testament to the power of collaboration in advancing clinical research. With Archer, we are laying the groundwork for a new era of digital innovation in clinical trials, one where data is transferred seamlessly, securely, and efficiently."
Looking Ahead
The data and insights gained from this live integration will inform future deployments of Archer across other NHS and European hospitals. This marks just the beginning of a broader initiative to scale this technology globally with approved sponsors, transforming the way clinical trials are conducted and accelerating the delivery of life-saving treatments to patients.
For more information about Archer and its role in modern clinical trials, visit IgniteData's website.
About IgniteData
IgniteData is the company shaping the future of clinical trials. Through its innovative digihealth platform, Archer, it is enhancing interoperability between Electronic Health Records (EHR) and key research applications such as Electronic Data Capture (EDC).
IgniteData is transforming the future of clinical trials through its cloud-based Virtual Research Assistant, Archer. A system-agnostic solution, Archer brings modern interoperability between EHR and key research systems, such as EDC, to provide seamless, secure transfer of clinically- validated data for clinical trials.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ignitedata-launches-cutting-edge-data-integration-platform-for-clinical-trials-at-cambridge-university-hospitals-302403035.html
SOURCE IgniteData
FAQ
What is the purpose of IgniteData's Archer platform in AstraZeneca's Phase 3 trial?
Where has AstraZeneca's Archer platform been successfully piloted before the Cambridge implementation?
When did the collaboration between IgniteData and AstraZeneca begin?
How many data points can the Archer platform transfer per patient in AZN's clinical trials?
